Elenco degli articoli con argomento «psoriasi»
Dermatologia11 ott 2021
Tildrakizumab for treatment of moderate to severe psoriasis
IntroductionTildrakizumab is a monoclonal antibody that targets the p19 subunit of IL-23, a crucial cytokine for Th17 cells.
06 set 2021
Psoriasis exacerbation after COVID-19 vaccination
Psoriasis exacerbation after COVID-19 vaccination
06 set 2021
Drug Survival of IL-12/23, IL-17 and IL-23 Inhibitors for Psoriasis Treatment
Drug survival analysis of biologic agents in psoriasis is of extreme importance
06 set 2021
Predictive factors of lack of response to adalimumab among bio-naive patients
Efficacy of anti-TNF-a agents seems inferior to IL-17 and IL-23 inhibitors.
05 lug 2021
Updates on the Treatment of Erythrodermic Psoriasis
Erythrodermic psoriasis (EP) is a rare variant of psoriasis, which is potentially life threatening and often resistant to conventional therapy.
28 giu 2021
A study of corticophobia in adult psoriasis patients
A study of corticophobia in adult psoriasis patients: a French cross-sectional observational study
07 giu 2021
Resident Memory T Cells
Tissue resident memory T cells (TRM) are a critical component of the immune system
07 giu 2021
A multi-center open-label study of apremilast
Palmoplantar pustulosis (PPP) is a chronic skin disease with painful erythematous scaly or crusty lesions and pustules on the palms and soles.
26 apr 2021
Drug Survival of IL-12/23
Drug survival analysis of biologic agents in psoriasis is of extreme importance, as it allows not only the evaluation of objective clinical outcomes
26 apr 2021
Maternal and Neonatal Outcomes in Pregnant Women
Psoriasis and psoriatic arthritis (PsA) are inflammatory diseases that affect women in their reproductive years.
22 apr 2021
Living EuroGuiDerm - Linee guida per il trattamento sistemico della psoriasi volgare
Vaccination against SARS-CoV-2 in people with psoriatic disease - Aprile 2021
20 apr 2021
La nuova linea con celastrol nel paziente con psoriasi
Nuova dermo-cosmesi per attenuare il prurito della psoriasi
23 mar 2021
Are biologics combined with methotrexate better
To investigate if the combination of biologics with methotrexate (MTX)
15 feb 2021
Skin Barrier Function in Psoriasis and Atopic Dermatitis
Multiple diagnostic tools are used to evaluate psoriasis and atopic dermatitis (AD) severity, but most of them are based on subjective components.
09 feb 2021
Therapeutics targeting the IL-23 and IL-17 pathway in psoriasis
Psoriasis is a chronic inflammatory disease characterised by sharply demarcated erythematous and scaly skin lesions accompanied by systemic manifestations.
13 gen 2021
Celastrol: un approccio dermocosmetico alla psoriasi da scoprire
Il Celastrol, ed il ruolo dell’emolliente nella psoriasi
15 dic 2020
La scienza dermocosmetica scopre una nuova molecola per la psoriasi
Studi recenti hanno evidenziato che il Celastrol agisce sui mediatori dell’infiammazione tipica della psoriasi
14 dic 2020
Immune checkpoint-mediated psoriasis
A multicentric European study of 115 patients from European Network for Cutaneous ADverse Event to Oncologic drugs (ENCADO) group
24 nov 2020
Characteristic of Chronic Plaque Psoriasis Patients Treated with Biologics in Italy during the COVID-19 Pandemic
Risk Analysis from the PSO-BIO-COVID Observational Study
03 nov 2020
Special aspects of biologics treatment in psoriasis: management in pregnancy, lactation, surgery, renal impairment, hepatitis and tuberculosis
Biologics are modern immunomodulatory drugs, whose use in the treatment of psoriasis has led to remarkable results in psoriatic patients. The administration of these agents in special population groups, such as patients with chronic infections and renal impairment, as well as perioperative, pregnant or lactating patients, has not been thoroughly addressed, mostly because these patients are excluded from clinical studies.